Keywords: Malignant melanoma, Market shares, Bristol-Myers, Yervoy, Roche, Zelboraf, GlaxoSmithKline, Dabrafenib, Trametinib, Decison Resources

Yervoy and Zelboraf accounted for two-thirds of malignant melanoma drug market in 2011; report

Article | 18 September 2012

Print This

The launches of Bristol-Myers Squibb’s (NYSE: BMY) immunotherapy Yervoy (ipilimumab) and Roche (ROG: SIX)/Genentech/Chugai/Daiichi Sankyo ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in